| Bioactivity | Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM[1]. |
| Target | IC50: 1.8 nM (IGF1R) |
| Invitro | Figitumumab (CP-751871) (152 pM-10 μM; 3 days) inhibits cancer cell proliferation[1].Figitumumab (1 μg/mL; 1 min or 24 h) induces the down-regulation of IGF-1R[2].Figitumumab inhibits IGF1-induced autophosphorylation of IGF1R with an IC50 of 0.42 nM, and indirectly inhibits AKT activation[2].Figitumumab recognizes the IGF-1R/IR heterodimer complex[2]. Cell Proliferation Assay[1] Cell Line: |
| In Vivo | Figitumumab (CP-751871) (31-125 μg/mouse; i.p.; once) induces the down-regulation of tumor associated IGF-1R in mice[2].Figitumumab (62.5-500 μg/mouse; i.p.; once) inhibits the growth of s.c. xenografts derived from colon (Colo-205), breast (MCF7), and lung (H460) cancer cell lines in mice[2]. Animal Model: |
| Name | Figitumumab |
| CAS | 943453-46-1 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Pavlicek A, et al. Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871). Mol Cancer Ther. 2013 Dec;12(12):2929-39. [2]. Cohen BD, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. 2005 Mar 1;11(5):2063-73. |